Overweight modifies the longitudinal association between uric acid and some components of the metabolic syndrome: The Tromsø Study by Norvik, Jon Viljar et al.
RESEARCH ARTICLE Open Access
Overweight modifies the longitudinal
association between uric acid and some
components of the metabolic syndrome:
The Tromsø Study
Jon V. Norvik1,3,6*, Hilde M. Storhaug1, Kirsti Ytrehus1,3, Trond G. Jenssen1,4, Svetlana N. Zykova1,5,
Bjørn O. Eriksen1,2 and Marit D. Solbu1,2
Abstract
Background: Elevated uric acid (UA) is associated with the presence of the metabolic syndrome (MetS). In a
prospective cohort study, we assessed whether baseline and longitudinal change in UA were risk factors for
development of MetS and its individual components.
Methods: We included 3087 women and 2996 men who had UA measured in the population based Tromsø
Study 1994–95. The participants were stratified according to body mass index (BMI). Endpoints were MetS and
each component of the syndrome after 7 years, according to the revised National Cholesterol Education Program’s
Adult Treatment Panel III (NCEP-ATP III) definition.
Results: Multiple logistic regression analyses showed that higher baseline UA was associated with higher odds
of developing elevated blood pressure in overweight subjects (BMI ≥ 25 kg/m2, odds ratio [OR] per 59 μmol/L
UA increase 1.44, 95 % confidence interval [CI] = 1.17–1.77, P = 0.001), but not in normal-weight subjects (BMI
< 25 kg/m2, P for interaction = 0.04). Overweight also modified the association between baseline UA and the
development of elevated fasting glucose (P for interaction = 0.01). UA was a predictor of MetS in all subjects
(OR per 59 μmol/L UA increase 1.29, 95 % CI 1.18–1.41, P < 0.001). Furthermore, longitudinal UA change was
independently associated with the development of MetS in all subjects (OR per 59 μmol/L UA increase over
7 years 1.28, 95 % CI 1.16–1.42, P < 0.001).
Conclusion: Increased levels of baseline UA independently predicted development of elevated blood pressure
and higher fasting glycemia in the overweight, but not the normal-weight subjects. Baseline UA and longitudinal
increase in UA over 7 years was associated with the development of MetS in all subjects. Whether increased UA should
be treated differently in normal-weight and overweight persons needs further study.
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Background
High levels of serum uric acid (UA) are prevalent in the
general population. In the National Health and Nutrition
Examination Survey (NHANES) 2007–2008 UA levels
higher than 339 μmol/L were found in 21.6 % of the
women, and among men 21.2 % had UA levels higher
than 416 μmol/L [1]. Similar prevalence has been found
in China [2]. The incidence and prevalence of hyperurice-
mia is increasing, as reflected by the increase in the inci-
dence and prevalence of gout since the 1960s [3]. In the
US, the prevalence of gout more than doubled between
1969 and 1985 [4], may have increased further over the
past two decades [1], and has paralleled a significant in-
crease in prevalence of hyperuricemia [1].
The metabolic syndrome (MetS) is a constellation of in-
terrelated risk factors that increases the risk of cardiovascu-
lar disease and type 2 diabetes [5]. MetS is associated with
more than two-fold risk of atherosclerotic cardiovascular
disease and cardiovascular death [6]. The prevalence of
MetS is high in most populations, and in the NHANES
2003–2006 about 34 % of US adults ≥20 years of age ful-
filled the MetS definition [7]. One study estimated the
worldwide prevalence of MetS to range from <10 % to as
much as 84 %, depending on region, sex, age and ethnicity
[8]. The prevalence of MetS increased significantly between
NHANES 1988–1994 and NHANES 1999–2006, and one
of the main reasons for this was the increase in abdominal
obesity [9]. Overweight and obesity is an increasing global
burden [10] and the number of overweight and obese is
projected to continue to grow into the future [11].
UA has been reported to be a risk factor for cardiovas-
cular disease or cardiovascular death in many studies
[12–14], but not all [15]. Studies have suggested that hy-
peruricemia is associated with all of the components of
MetS individually: elevated blood pressure [16], obesity
[17], high triglycerides [18], low HDL [18] and elevated
fasting glucose [19]. Several cross-sectional studies have
shown an association between UA and MetS [20, 21], al-
though, after multivariable adjustment, the association dis-
appeared in one study [22]. The role of UA as an
independent predictor of the development of MetS has also
been examined in several prospective studies. In one study
no such association was found [23]. A recent meta-analysis
comprising 11 prospective studies concluded that there was
an independent, linear dose–response relationship between
increasing UA and the development of MetS [24]. As the
prevalence of hyperuricemia increases along with the preva-
lence of overweight and MetS, the causal association be-
tween the phenomena remains unsolved. The purposes of
the present prospective cohort study were to examine the
role of UA and change in UA as a predictor of the MetS
and its components after 7 years, and to assess to what ex-




The Tromsø Study is a series of population-based, pro-
spective surveys of inhabitants of the municipality of
Tromsø, Norway [25]. In 1994–1995, 26,969 subjects were
investigated (77 % of eligible subjects). Out of these, all par-
ticipants aged 55–74 years, as well as smaller (5–8 %) ran-
dom samples of the other age groups <85 years were
invited to the more extensive second-visit examination, and
7445 subjects attended (75 % of eligible subjects). Subjects
who attended the second visit in 1994–1995 were eligible
for the next survey of 2001–2002. In this survey, 6852 sub-
jects who had partaken in the second visit in 1994–1995,
participated (89 % of eligible subjects). The number of sub-
jects who died between the two studies was 495. In the
present study, we excluded those with missing serum UA
analyses (n = 405), prevalent diabetes at baseline (n = 282;
defined as Hba1c ≥6.5 %, non-fasting glucose ≥10.0 mmol/
L, under anti-diabetic treatment or self-reported diabetes),
and the under-weight subjects (n = 82, body mass index
[BMI] < 18.5 kg/m2). Thus, the final study cohort consisted
of 6083 subjects at baseline. The University of Tromsø
conducted The Tromsø Study in cooperation with The
National Health Screening Service. The Regional Commit-
tee for Medical Research Ethics approved the study, and all
participants gave their written consent.
Measurements
All participants provided information on diabetes, alcohol
and smoking habits, current use of medication and physical
activity through a self-administered questionnaire. Experi-
enced nurses made anthropometric measurements. We cal-
culated BMI as weight (kg)/height (m)2. BMI was
dichotomized into normal-weight (BMI < 25 kg/m2) and
overweight (BMI ≥ 25 kg/m2). Blood pressure was re-
corded in triplet after 5-min seating; the mean of the
second and third measurement was used. Physical ac-
tivity was classified as active (≥1 h physical activity with
prominent perspiration or breathlessness per week) or
inactive (all others). Smoking habits were classified as
non-smokers or current smokers. Alcohol intake was
classified as teetotalers, 1–7 units/week and >7 units a
week. Non-fasting blood samples were drawn and time
since last meal was recorded. Serum UA was measured
by photometry with COBAS® instruments (Roche diag-
nostics, Switzerland) using an enzymatic colorimetric
test, the uricase/PAP method. Change in UA (ΔUA)
was calculated as serum UA in 2001–2002 minus serum
UA in 1994–1995. Creatinine was originally analyzed
by a modified Jaffe reaction, but because of a possible
drift in the results between baseline and follow-up, 111
plasma samples from the 1994–1995 survey and 142
samples from the 2001–2002 survey were thawed and
reanalyzed with an enzymatic method (Modular P/Roche
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Diagnostics) in 2006, as previously described [26]. Values
were fitted to a linear regression model, and recalibrated
creatinine values were calculated for all participants. Esti-
mated glomerular filtration rate (eGFR) was calculated
according to the CKD-EPI formula [27]. Detailed descrip-
tions of measurements of lipids and HbA1c have been
published previously [28].
The metabolic syndrome
Our definition of MetS was based on the revised National
Cholesterol Education Program’s Adult Treatment Panel III
(NCEP-ATP III) criteria as published by the American
Heart Association [5]. Because our data lacked fasting
blood samples, we adjusted the definition of elevated
triglycerides and elevated glucose. For the definition of ele-
vated fasting glucose, we set the cut off at ≥7.8 mmol/L if
time since last meal was under 4 h and at ≥5.6 mmol/L if
time since last meal was at least 4 h. For the definition of
elevated triglycerides, we set the cut-off at ≥2.28 mmol/L if
time since last meal was under 4 h, as non-fasting triglycer-
ide levels are on average 20 to 30 % higher than fasting
levels [29], and ≥1.7 mmol/L if time since last meal was at
least 4 h. Thus, the definition of MetS in this study is any
three (or more) out of the following five criteria: increased
waist circumference (≥88 cm in women and ≥102 cm in
men), elevated triglycerides (triglycerides ≥1.7 mmol/L if time
since last meal ≥4 h, ≥ 2.28 mmol/L if time since last meal
<4 h or use of lipid-lowering drugs), reduced HDL-cholesterol
(HDL< 1.30 mmol/L in women and <1.03 mmol/L in men),
elevated blood pressure (≥130 mm Hg systolic blood
pressure, ≥ 85 mm Hg diastolic blood pressure or an-
tihypertensive drug treatment) and elevated fasting
glucose (glucose ≥ 5.6 mmol/L if time since last meal
≥4 h, ≥7.8 mmol/L if time since last meal <4 h or on
treatment for elevated glucose).
Statistics
Data are given as mean ± standard deviation (SD). Inde-
pendent sample t-tests and chi square tests were applied
to compare baseline variables between participants with
normal-weight and overweight. In each of these groups,
we assessed Pearson’s correlation coefficient between
UA and the baseline variables. We conducted multiple
binary logistic regression analyses with each single cri-
terion of MetS and MetS (any three criteria or more) in
2001–2002 as dependent variables and uric acid as an
independent variable in separate models. Covariates were
sex, age, systolic blood pressure, total cholesterol, current
smoking, physical activity, Hba1c, eGFR, alcohol con-
sumption, use of diuretics and waist circumference at
baseline. In each of these analyses, we only included the
subjects who did not fulfill the MetS criterion of interest
at baseline. We ran the analyses both with the entire co-
hort and stratified into normal-weight and overweight
(BMI < 25 kg/m2 and BMI ≥ 25 kg/m2) at baseline, and
interaction between UA and the BMI group was tested for.
We also checked for interactions between UA and gender
and UA and a BMI-cutoff of obesity (BMI < 30 kg/m2 and
BMI ≥ 30 kg/m2) for MetS and each of the MetS criteria.
The logistic regression analyses were repeated for the group
of subjects who did not have MetS at baseline. Finally, we
assessed whether ΔUA was associated with MetS and its
components by adding ΔUA as an independent variable to
each model. These analyses were also run in the group
without MetS at baseline. Two-sided P values < 0.05 were
considered statistically significant. We did all the analyses
using SPSS software version 22.0 (IBM Corp. Released
2013. IBM SPSS Statistics for Windows, Version 22.0.
Armonk, NY: IBM Corp).
Results
Baseline characteristics
Baseline characteristics of the cohort divided into normal-
weight (BMI < 25 kg/m2) and overweight (BMI ≥ 25 kg/m2)
are shown in Table 1. The differences between the two
groups were statistically significant for all the variables. Be-
ing overweight, compared to normal-weight, was associated
with male gender, older age, and generally a more adverse
cardiovascular risk profile, including higher blood pressure,
lower eGFR and a poorer lipid profile. On the other hand,
there was a larger proportion of smokers in the normal-
weight stratum. Also shown in Table 1 is the correlation
between each variable and UA. In addition to gender, waist
circumference, triglycerides, HDL and MetS correlated
strongest with UA, whereas eGFR, use of diuretics, alcohol
consumption and blood pressure correlated weaker with
UA. The rest of the variables displayed a very weak correl-
ation with UA or no correlation at all. Median time since
last meal at baseline was between 2 and 3 h, 16.6 % had
at least 4 h since last meal, and 6.1 % had at least 8 h
since last meal. In this cohort, 57.9 % of the subjects
were overweight (BMI ≥ 25 kg/m2) and 13.5 % were
obese (BMI ≥ 30 kg/m2).
Associations between baseline UA and subsequent
changes in the components of MetS stratified by BMI
Figure 1 displays the multivariable adjusted odds ratio
(OR) of 59 μmol/L (1 mg/dL) UA increase at baseline
for acquiring each component of MetS and MetS (three
or more components of MetS) after 7 years, stratified by
baseline BMI. Each outcome was assessed in the subjects
who did not fulfill the criteria for the outcome of inter-
est at baseline. Among the normal-weight individuals, 669
subjects were normotensive at baseline according to the
MetS criteria. After 7 years, 251 of them had developed el-
evated blood pressure. Baseline UA was not a predictor of
elevated blood pressure in this group. Among the 450
overweight subjects who were normotensive at baseline,
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227 had developed elevated blood pressure 7 years later.
Baseline UA was an independent predictor of elevated
blood pressure in the overweight (OR per 59 μmol/L UA
1.44, 95 % confidence interval [CI] 1.17–1.77, P = 0.001).
The interaction between the BMI-cutoff and UA for the
prediction of new cases of elevated blood pressure was sig-
nificant (P = 0.04). There were no statistically significant in-
teractions between neither UA and gender nor UA and a
BMI-cutoff of obesity (BMI < 30 kg/m2 and BMI ≥ 30 kg/
m2) for any of the outcomes.
BMI also modified the association between UA at base-
line and new cases of elevated fasting glucose after 7 years
(Fig. 1). In the overweight, baseline UA predicted this out-
come (OR per 59 μmol/L UA increase 1.20, 95 % CI =
1.10–1.32, P < 0.001), whereas baseline UA was not signifi-
cantly associated with new onset fasting glucose elevation
for subjects with normal-weight (P for interaction = 0.01).
There was no interaction between UA and the BMI cut-
off for elevated triglycerides and low HDL cholesterol ac-
cording to MetS criteria (P for interaction = 0.39 for both),
Table 1 Cohort characteristics according to classification by body mass index (BMI) definition of normal-weight/overweight














Age, years 58.8 ±11.3 0.09 <0.001 60.9 ±9.1 −0.08 <0.001 <0.001
Sex Men 1149 45.0 % 0.51 <0.001 1847 52.4 % 0.44 <0.001 <0.001
Women 1407 55.0 % 1680 47.6 %
Systolic blood pressure, mm Hg 139.5 ±21.7 0.11 <0.001 148.3 ±22.1 0.03 0.046 <0.001
Waist circumference, cm Men 87.7 ±5.6 0.45 <0.001 99.5 ±7.6 0.39 <0.001 <0.001
Women 77.5 ±6.3 91.0 ±9.5
Serum HDL, mmol/L 1.65 ±0.45 −0.28 <0.001 1.46 ±0.40 −0.35 <0.001 <0.001
Uric acid μmol/L Men 334.1 ±72.9 – – 377.7 ±88.4 – – <0.001
Women 254.5 ±63.4 – – 298.9 ±72.0 – – <0.001
Triglycerides, mmol/L 1.27 ±0.67 0.45 <0.001 1.73 ±0.98 0.55 <0.001 <0.001
Plasma glucose, mmol/L 4.64 ±0.58 0.03 0.094 4.82 ±0.62 0.11 <0.001 <0.001
HBA1C, % 5.36 ±0.35 0.03 0.229 5.42 ±0.37 0.05 0.003 <0.001
Total cholesterol, mmol/L 6.56 ±1.33 0.07 <0.001 6.89 ±1.25 0.01 0.666 <0.001
eGFR, mL/min/1.73 m2 94.6 ±13.6 −0.23 <0.001 91.6 ±13.0 −0.14 <0.001 <0.001
Use of diuretics, n 23 0.9 % 0.12 <0.001 78 2.2 % 0.13 <0.001 <0.001
Use of allopurinol, n 0 – – – 15 0.4 % 0.03 0.113 0.001
Daily smoker, n 1026 40.1 % −0.01 0.503 935 26.5 % 0.03 0.131 <0.001
Alcohol consumption, teetotalers, n 1277 50.0 % 0.14 <0.001 1936 54.90 % 0.19 <0.001 0.001
Alcohol consumption, 1–7 units/week, n 1186 46.4 % – – 1435 40.70 % – – –
Alcohol consumption, > 7 units/week, n 93 3.6 % – – 156 4.40 % – – –
Physical activity, n 608 23.8 % 0.04 0.044 720 20.4 % 0.03 0.086 0.002
Elevated blood pressure, n 1696 66.4 % 0.14 <0.001 2943 83.4 % 0.11 <0.001 <0.001
Central obesity, n 95 3.7 % −0.04 0.058 1631 46.2 % 0.06 <0.001 <0.001
Elevated triglycerides, n 252 9.9 % 0.33 <0.001 894 25.3 % 0.41 <0.001 <0.001
Low HDL, n 282 11.0 % 0.05 0.007 724 20.5 % 0.18 <0.001 <0.001
Elevated fasting glucose, n 15 0.6 % 0.01 0.666 65 1.8 % 0.03 0.104 <0.001
Metabolic syndrome, n 91 3.6 % 0.20 <0.001 788 22.3 % 0.32 <0.001 <0.001
The first column in each strata provides means for the continuous variables and numbers for the categories
Elevated blood pressure = blood pressure ≥130/85 mm Hg or treated for hypertension, elevated triglycerides = triglycerides ≥2.28 mmol/L if time since last meal
<4 h and ≥1.7 mmol/L if time since last meal ≥4 h or use of lipid lowering drugs, low HDL = HDL < 1.03 mmol/L in men or <1.30 mmol/L in women, elevated
fasting glucose = glucose ≥ 7.8 mmol/L if time since last meal <4 h and ≥5.6 mmol/L if time since last meal ≥4 h or treated for elevated glucose, central
obesity = waist circumference ≥ 102 cm in men or ≥88 cm in women, MetS = three or more MetS components
Abbreviations: BMI body mass index, UA uric acid, SD standard deviation, HDL high-density lipoprotein, HBA1c hemoglobin A1c, eGFR estimated glomerular
filtration rate
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and UA did not significantly predict the development of
central obesity according to the MetS criteria in either
group.
The association between UA and new cases of MetS
Results of unstratified multivariable logistic regression
analyses of the subjects without MetS at baseline are
displayed in Table 2. In this group, 611 subjects had
MetS 7 years later, and baseline UA was a predictor of
this outcome (OR per 59 μmol/L increase 1.29, 95 %
CI = 1.18–1.41, P < 0.001).
Change in UA as a risk factor for MetS and its
components
Change in UA over 7 years as a predictor of MetS
and its single components in 2001–2002 was assessed
in multiple logistic regression models. The results are
shown in Table 3. An increase in UA by 59 μmol/L over 7
years from baseline implied an increase in odds of MetS of
28 %. UA increase was also an independent risk factor for
new cases of elevated blood pressure, elevated triglycerides,
low HDL and central obesity. However, longitudinal UA
increase was not a risk factor for incident elevated fasting
glucose.
Discussion
In this large prospective study of subjects without dia-
betes from the general population, elevated UA at base-
line was independently associated with increased risk of
elevated blood pressure in the overweight individuals 7
years later. We found no association between UA and
future elevated blood pressure in the normal-weight sub-
jects. Moreover, UA at baseline predicted new-onset im-

























BMI < 25 kg/m²
Fig. 1 Multivariable logistic regression with baseline serum uric acid (UA) as predictor of the metabolic syndrome and its components after 7 years,
stratified into normal-weight and overweight at baseline by body mass index (BMI). The odds ratio is per 59 μmol/L increase of UA. Bars represent odds
ratio; grey bars the normal-weight subjects (BMI < 25 kg/m2) and black bars the overweight subjects (BMI≥ 25 kg/m2). Whiskers represent 95 %
confidence interval. The group includes the subjects without each component of MetS of interest or MetS (three or more components) at baseline.
Covariates: baseline sex, age, systolic blood pressure, total cholesterol, current smoking, physical activity, HbA1c, eGFR, alcohol consumption, use of
diuretics, and waist circumference. * = P for interaction with BMI-cut-off <0.05. Elevated blood pressure: blood pressure ≥130/85 mm Hg or treated for
hypertension, elevated triglycerides: triglycerides ≥2.28 mmol/L if time since last meal <4 h and ≥1.7 mmol/L if time since last meal ≥4 h or use of lipid
lowering drugs, low HDL = HDL < 1.03 mmol/L in men or <1.30 mmol/L in women, elevated fasting glucose = glucose ≥7.8 mmol/L if time since last
meal <4 h and ≥5.6 mmol/L if time since last meal ≥4 h or treated for elevated glucose, central obesity = waist circumference ≥102 cm in men or
≥88 cm in women, MetS = three or more MetS components. Abbreviations: HDL high-density lipoprotein, BMI body mass index, MetS metabolic
syndrome, UA uric acid, HBA1c hemoglobin A1c, eGFR estimated glomerular filtration rate
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in the normal-weight group. Baseline UA was a predictor
of MetS in all subjects. Finally, a longitudinal increase in
UA of 59 μmol/L over 7 years raised the odds of develop-
ing MetS by 28 %.
The association between UA and MetS is in accord-
ance with previous prospective studies [17, 30, 31]. Few
studies have examined the association between longitu-
dinal UA change and MetS. In a healthy Japanese cohort,
no significant association was found between 1 mg/dL
(59 μmol/L) UA increase and incident MetS [32]. How-
ever, in the Japanese study, follow-up time was shorter
than in our study, and the authors did not adjust for
baseline UA. These methodological differences may in
part explain the discrepancies between the results of our
study and the study from Japan.
To the best of our knowledge, there are no other
studies of this scale where the population is stratified
into normal-weight/overweight before examining the
association between UA and MetS and its components.
A small study (n = 69) from the United Arab Emirates
examined the univariable relationship between a set of
biomarkers, among them UA, and components of MetS
in healthy, young females, stratified into normal-weight
(BMI ≤ 25 kg/m2), overweight (BMI > 25, < 30 kg/m2),
and obese (BMI ≥ 30 kg/m2) [33]. This study found sta-
tistically significant correlations between UA and the
waist circumference and triglycerides components only,
and the associations were confined to the obese group.
The authors found no significant correlation between
UA and blood pressure in the strata; this may be due to
small sample size and a population of uniform age and
sex. In our study, we did not find any statistically sig-
nificant interaction between the BMI-cutoff of obesity
(BMI < 30 kg/m2 and BMI ≥ 30 kg/m2) for neither MetS
nor any of its components. This may be due to a small
group of obese in our cohort.
Table 2 Multivariable logistic regression with baseline serum uric acid (UA) as a predictor of the metabolic syndrome (MetS) and its
components after seven years, unstratified. The odds ratio (OR) is per 59 μmol/L increase of UA. The group includes the subjects
without MetS at baseline
Number Cases OR 95 % CI P value
Risk of elevated blood pressure 3701 2847 1.15 [1.04–1.27] 0.006
Risk of elevated triglycerides 3693 941 1.32 [1.22–1.42] <0.001
Risk of low HDL 3690 553 1.27 [1.16–1.39] <0.001
Risk of elevated fasting glucose 3689 333 1.13 [1.02–1.26] 0.021
Risk of central obesity 3677 1031 1.07 [0.97–1.18] 0.130
Risk of MetS 3660 611 1.29 [1.18–1.41] <0.001
Covariates: sex, age, systolic blood pressure, total cholesterol, current smoking, physical activity, HbA1c, eGFR, use of diuretics, alcohol consumption, and
waist circumference
Elevated blood pressure = blood pressure ≥ 130/85 mm Hg or treated for hypertension, elevated triglycerides = triglycerides ≥ 2.28 mmol/L if time since last meal
<4 h and ≥1.7 mmol/L if time since last meal ≥4 h or use of lipid lowering drugs, low HDL = HDL < 1.03 mmol/L in men or <1.30 mmol/L in women, elevated
fasting glucose = glucose ≥ 7.8 mmol/L if time since last meal <4 h and ≥5.6 mmol/L if time since last meal ≥4 h or treated for elevated glucose, central
obesity = waist circumference ≥ 102 cm in men or ≥88 cm in women, MetS = three or more MetS components
Abbreviations: UA uric acid, OR odds ratio, BMI body mass index, CI confidence interval, HDL high-density lipoprotein, HBA1c hemoglobin A1c, eGFR estimated
glomerular filtration rate, MetS metabolic syndrome
Table 3 Multivariable logistic regression with longitudinal serum uric acid change (ΔUA) from baseline to seven years later as a
predictor of the metabolic syndrome and its components after seven years. The odds ratio (OR) is per 59 μmol/L UA increase.
The group includes the subjects without MetS at baseline
Number Cases OR 95 % CI P value
Risk of elevated blood pressure 3507 2693 1.16 [1.02–1.31] 0.021
Risk of elevated triglycerides 3507 888 1.20 [1.10–1.31] <0.001
Risk of low HDL 3506 528 1.18 [1.07–1.31] 0.001
Risk of elevated fasting glucose 3506 320 0.97 [0.86–1.10] 0.636
Risk of central obesity 3484 978 1.49 [1.33–1.66] <0.001
Risk of MetS 3477 586 1.28 [1.16–1.42] <0.001
Covariates: sex, age, systolic blood pressure, total cholesterol, current smoking, physical activity, HbA1c, eGFR, alcohol consumption, use of diuretics, waist
circumference, baseline UA
Elevated blood pressure = blood pressure ≥ 130/85 mm Hg or treated for hypertension, elevated triglycerides = triglycerides ≥ 2.28 mmol/L if time since last meal
<4 h and ≥1.7 mmol/L if time since last meal ≥4 h or use of lipid lowering drugs, low HDL = HDL < 1.03 mmol/L in men or <1.30 mmol/L in women, elevated
fasting glucose = glucose ≥ 7.8 mmol/L if time since last meal <4 h and ≥5.6 mmol/L if time since last meal ≥4 h or treated for elevated glucose, central
obesity = waist circumference ≥ 102 cm in men or ≥88 cm in women, MetS = three or more MetS components
Abbreviations: ΔUA uric acid change, UA uric acid, OR odds ratio, BMI body mass index, CI confidence interval, HDL high-density lipoprotein, HBA1c hemoglobin
A1c, eGFR estimated glomerular filtration rate, MetS metabolic syndrome
Norvik et al. BMC Cardiovascular Disorders  (2016) 16:85 Page 6 of 9
The association between hypertension and UA was
first noted in the 1870s and has been demonstrated
in numerous publications. In a recent meta-analysis,
UA increase was reported to be associated with a sta-
tistically significant elevation in incident hypertension
[16]. It has been claimed that an elevated serum UA
is the independent risk factor for hypertension that is
the most reproducible to date [34]. A multitude of
studies, in an effort to explain how hyperuricemia can
lead to hypertension and cardiovascular disease, have
proposed interlinked mechanisms such as endothelial
dysfunction and reduction in endothelial nitric oxide
(NO) levels [35], oxidative stress [36], activation of
the renin-angiotensin-aldosterone-system (RAAS) [37]
and renal microvascular lesions [38]. However, we
found that UA was a predictor of elevated blood
pressure in the overweight, but not in the normal-
weight. Few studies have explored this phenomenon.
The precursor of UA is xanthine, and the reaction from
the latter to the former is catalyzed by the enzyme
xanthine oxidoreductase (XOR), which can exist in two
forms, xanthine dehydrogenase (XDH) or xanthine oxi-
dase (XO) [39]. The enzyme is mostly in its XDH form,
but can be transformed into XO by proteolytic cleavage or
oxidation. In the XO form, reactive oxygen species are a
by-product of the reaction of xanthine to UA [40]. There-
fore, under certain circumstances, increased activity of
XO, detected as elevated production of UA, will lead to
increased oxidative stress, which, in turn, can be detri-
mental in the state of reduced antioxidant capacity that
accumulated fat creates [41]. Furthermore, UA can
affect adipocytes by inducing upregulation of pro-
inflammatory factors and downregulation of the insu-
lin sensitizer and anti-inflammatory factor adiponectin
[42]. Adiponectin is negatively associated with BMI
and body-fat [43]. Since low levels of adiponectin is
associated with the development of hypertension [44]
and insulin resistance [45], it could be speculated that adi-
ponectin is part of the link between UA and elevated
blood pressure and insulin resistance, and explain why UA
is associated with new onset elevated blood pressure and
impaired fasting glucose in the overweight but not the
normal-weight in our study. Furthermore, a study
found increased angiotensinogen levels in the hyper-
tensive overweight (BMI ≥ 25 kg/m2), compared to the
hypertensive normal-weight (BMI < 25 kg/m2), in the
presence of hyperuricemia [46], and a rodent model
demonstrated that UA-mediated upregulation of adi-
pose RAAS caused insulin resistance [47]. UA might
also directly contribute to the development of insulin
resistance in adipose tissue, possibly through redox
modulation [48]. These could also be mechanisms in
which UA is associated with overweight-related ele-
vated blood pressure and elevated fasting glucose.
Epidemiologically, UA is associated with insulin resist-
ance [49], and the development of insulin resistance is
often preceded by hyperuricemia [50]. MetS does not
comprise a uniform group of subjects; Sperling et al. of
The Cardiometabolic Think Tank present a subtype where
insulin resistance is dominant [51]. An association be-
tween hyperuricemia and insulin resistance could in part
explain the development of MetS.
The present study has important strengths: the large
size, solid attendance rate, long follow-up time, use of
UA as a continuous variable, and the ability to correct
for confounders such as eGFR, use of diuretics and all
the traditional cardiovascular risk factors. However, a
major shortcoming of our study is the lack of fasting
blood samples. In particular, glucose and triglycerides,
and thereby the definition of MetS, are affected by this.
The incorporation of time since last meal and adjust-
ment of the cut-offs in the definition of elevated fasting
glucose and elevated triglycerides compensated in part,
but not fully, for this limitation. In addition, only a single
measurement of serum UA was done in each survey.
Another shortcoming of this study may be the fact that
our baseline data were collected 21–22 years ago, and
14–15 years have passed since follow-up. Both lifestyles
and pharmacological treatment have changed in that
time. However, if the effects of overweight on UA’s asso-
ciation with MetS can be reproduced in studies on
newer data, our findings may be even more relevant as
overweight and obesity is an even greater challenge in
the world of today. That our study population comprised
largely of healthy, middle-aged to elderly Caucasians can
be viewed as both a weakness and a strength; the results
may not be generalizable to dissimilar populations, but
the homogeneity of our cohort may have prevented dilu-
tion of our findings due to important diversities in base-
line properties.
Conclusion
In a large cohort from the general population, baseline
UA was independently associated with future cases of
elevated blood pressure and elevated fasting glucose in
overweight subjects, but not normal-weight individuals.
Both elevated baseline UA and longitudinal increase in
UA over 7 years from baseline was associated with the
development of MetS in all subjects. These findings war-
rant further studies to examine the exact causal relation-
ship between UA and MetS, in overweight as well as in
normal-weight individuals, and to assess whether treat-
ment strategies need to be targeted differentially accord-
ing to BMI.
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